MDR1-deficient genotype in Collie dogs hypersensitive to the P-glycoprotein substrate ivermectin

European Journal of Pharmacology

Volumn 460, Issue 2-3, 2003, Pages 85-91

  Roulet, Alain ^a   Puel, Olivier ^a   Gesta, Stéphane ^a   Lepage, Jean François ^a   Drag, Marlene ^b   Soll, Mark ^b   Alvinerie, Michel ^a   Pineau, Thierry ^a  

^a CEMAGREF   (France)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

(Collie); (Dog); Hypersensitivity; Ivermectin; MDR (multidrug resistance); P glycoprotein

Indexed keywords

COMPLEMENTARY DNA; GLYCOPROTEIN P; IVERMECTIN;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOG; EXON; FEMALE; FRAMESHIFT MUTATION; GENE DELETION; GENETIC CODE; GENOTYPE; HOMOZYGOSITY; HYPERSENSITIVITY; MALE; MULTIDRUG RESISTANCE; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; WILD TYPE;

EID: 0037462462     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02955-2     Document Type: Article

References (26)

1. Campbell W.C. Ivermectin, an antiparasitic agent. Med. Res. Rev. 13:1993;61-79.
2. Campbell W.C., Benz G.W. Ivermectin: a review of efficacy and safety. J. Vet. Pharmacol. Ther. 7:1984;1-16.
3. Conrad S., Viertelhaus A., Orzechowski A., Hoogstraate J., Gjellan K., Schrenk D., Kauffmann H.M. Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology. 156:2001;81-91.
4. De Silva N., Guyatt H., Bundy D. Anthelmintics. A comparative review of their clinical pharmacology. Drugs. 53:1997;769-788.
5. Didier A., Loor F. The abamectin derivative ivermectin is a potent P-glycoprotein inhibitor. Anti-Cancer Drugs. 7:1996;745-751.
6. Eytan G.D., Kuchel P.W. Mechanism of action of P-glycoprotein in relation to passive membrane permeation. Int. Rev. Cyt. 190:1999;175-250.
7. Fassler P.E., Tranquilli W.J., Paul A.J., Soll M.D., DiPietro J.A., Todd K.S. Evaluation of the safety of ivermectin administered in a beef-based formulation to ivermectin-sensitive Collies. J. Am. Vet. Med. Assoc. 199:1991;457-460.
8. Grobet L., Martin L.J., Poncelet D., Pirottin D., Brouwers B., Riquet J., Schoeberlein A., Dunner S., Menissier F., Massabanda J., Fries R., Hanset R., Georges M. A deletion in the bovine myostatin gene causes the double-muscled phenotype in cattle. Nat. Genet. 17:1997;71-74.
9. Lankas G.R., Cartwright M.E., Umbenhauer D. P-glycoprotein deficiency in a subpopulation of CF-1 mice enhances avermectin-induced neurotoxicity. Toxicol. Appl. Pharmacol. 143:1997;357-365.
10. Leveille-Webster C.R., Arias I.M. The biology of the P-glycoproteins. J. Membr. Biol. 143:1995;89-102.
11. Martin R.J. Modes of action of anthelmintic drugs. Vet. J. 154:1997;11-34.
12. Mealey K.L., Bentjen S.A., Gay J.M., Cantor G.H. Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene. Pharmacogenetics. 11:2001;727-733.
13. Nobmann S., Bauer B., Fricker G. Ivermectin excretion by isolated functionally intact brain endothelial capillaries. Br. J. Pharmacol. 132:2001;722-728.
14. Paul A.J., Tranquilli W.J., Seward R.L., Todd K.S. Jr., DiPietro J.A. Clinical observations in Collies given ivermectin orally. Am. J. Vet. Res. 48:1987;684-685.
15. Paul A.J., Tranquilli W.J., Todd K.S., Wallace D.H., Soll M.D. Evaluating the safety of administration high doses of a chewable ivermectin tablet to Collies. Vet. Med. 86:1991;623-625.
16. Paul A.J., Tranquilli W.J., Hutchens D.E. Safety of moxidectin in avermectin-sensitive Collies. Am. J. Vet. Res. 61:2000;482-483.
17. Pouliot J.F., L'Heureux F., Liu Z., Prichard R.K., Georges E. Reversal of P-glycoprotein-associated multidrug resistance by ivermectin. Biochem. Pharmacol. 53:1997;17-25.
18. Pulliam J.D., Seward R.L., Henry R.T., Steinberg S.A. Investing ivermectin toxicity in Collies. Vet. Med. 1985;33-40.
19. Schinkel A.H., Smit J.J., van Tellingen O., Beijnen J.H., Wagenaar E., van Deemter L., Mol C.A., van der Valk M.A., Robanus-Maandag E.C., Te Riele H.P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell. 77:1994;491-502.
20. Schinkel A.H., Wagenaar E., Mol C.A., Van Deemter L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 97:1996;2517-2524.
21. Sutherland I.H., Campbell W.C. Development, pharmacokinetics and mode of action of ivermectin. Acta Leiden. 59:1990;161-168.
22. Tang-Wai D.F., Kajiji S., DiCapua F., de Graaf D., Roninson I.B., Gros P. Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators. Biochemistry. 34:1995;32-39.
23. Tranquilli W.J., Paul A.J., Todd K.S. Assessment of toxicosis induced by high-dose administration of milbemycin oxime in Collies. Am. J. Vet. Res. 52:1991;1170-1172.
24. Tsuji A. P-glycoprotein-mediated efflux transport of anticancer drugs at the blood-brain barrier. Ther. Drug Monit. 20:1998;588-590.
25. Umbenhauer D.R., Lankas G.R., Pippert T.R., Wise L.D., Cartwright M.E., Hall S.J., Beare C.M. Identification of a P-glycoprotein-deficient subpopulation in the CF-1 mouse strain using a restriction fragment length polymorphism. Toxicol. Appl. Pharmacol. 146:1997;88-94.
26. Yamazaki M., Neway W.E., Ohe T., Chen I., Rowe J.F., Hochman J.H., Chiba M., Lin J.H. In vitro substrate identification studies for P-glycoprotein-mediated transport: species difference and predictability of in vivo results. J. Pharmacol. Exp. Ther. 296:2001;723-735.